CHF 3381 is an NMDA antagonist and monoamine oxidase inhibitor under development with Chiesi for the treatment of neuropathic pain. Preclinical studies show that the agent acts as a reversible and competitive inhibitor of human monoamine oxidases A and B.At the 1st Annual BioPartnering North America (BPN-2003) it was stated that CHF 3381 is being evaluated for the treatment of neuropathic pain. Preliminary data also suggested that CHF 3381 may have neuroprotective activity.In June 2003, Chiesi announced the completion of a phase I trial in France, and is proceeding with a proof-of-concept study in Denmark.[1]CHF 3381 is covered by European patent application EP 951465 (expires on 15 July 2017), and US patent No. 6,114,391 (issued on 5 September 2000). Other patents are granted or pending in 20 countries. Chiesi also has rights to the European patent application for use of glycinamide derivatives (including CHF 3381) in the treatment of chronic pain.[2]